Hot Pursuit     28-Jan-22
Eris Lifesciences Q3 PAT grows 11.7% YoY to Rs 100 cr
Eris Lifesciences reported a 11.7% increase in consolidated net profit to Rs 100.8 crore on a 7% rise in revenue from operations to Rs 332.2 crore in Q3 FY22 over Q3 FY21.
Consolidated profit before tax stood at Rs 108.9 crore in Q3 FY22, rising 9.75% from Rs 99.2 posted in the same quarter last year. EBITDA grew by 13.5% year on year to Rs 121.7 crore in Q3 FY22. Meanwhile, the drug company's EBITDA margin improved to 36.6% in Q3 FY22 from 34.5% in Q3 FY21.

The company said it grew at 7.8% in Q3 FY22 as compared to IPM growth of 5.7%, outperforming IPM in cardio-metabolic, CNS & women's health therapies.

Shares of Eris Lifesciences were trading 0.36% lower at Rs 706.30 on BSE. The result was announced during market hours today, 28 January 2022.

Eris Lifesciences is engaged in manufacturing, marketing and selling of generics within the chronic and acute categories of the Indian pharmaceutical market.

Previous News
  ERIS Lifesciences standalone net profit declines 55.02% in the March 2024 quarter
 ( Results - Announcements 21-May-24   17:47 )
  Board of ERIS Lifesciences approves composite scheme of arrangement
 ( Corporate News - 21-May-24   18:42 )
  Volumes jump at MTAR Technologies Ltd counter
 ( Hot Pursuit - 09-Nov-23   14:30 )
  ERIS Lifesciences allots 18,037 equity shares under ESOP
 ( Corporate News - 09-Sep-22   11:38 )
  ERIS Lifesciences fixes record date for interim dividend
 ( Market Beat - Reports 06-Mar-20   13:31 )
  ERIS Lifesciences consolidated net profit rises 8.47% in the March 2024 quarter
 ( Results - Announcements 21-May-24   17:48 )
  Board of ERIS Lifesciences approves NCD issuance up to Rs 1250 cr
 ( Corporate News - 21-May-24   18:40 )
  Volumes jump at ERIS Lifesciences Ltd counter
 ( Hot Pursuit - 31-Jan-24   11:00 )
  ERIS Lifesciences to conduct board meeting
 ( Corporate News - 06-Mar-20   17:21 )
  ERIS Lifesciences allots 14,717 equity shares under ESOP
 ( Corporate News - 21-Jun-22   19:51 )
  ERIS Lifesciences consolidated net profit rises 17.66% in the March 2022 quarter
 ( Results - Announcements 03-May-22   15:49 )
Other Stories
  Tata Motors JLR wholesale rises 5% YoY in Q1
  06-Jul-24   13:01
  Marico's domestic biz sees modest volume growth in Q1
  06-Jul-24   12:25
  Titan revenue rises 9% YoY, adds 61 stores in Q1
  06-Jul-24   11:09
  Dabur India expects mid to high digit revenue growth in Q1
  06-Jul-24   10:40
  Dhanlaxmi Bank gains as gross advances rises 6% YoY in Q1 FY25
  05-Jul-24   15:27
  HDFC Bank Ltd leads losers in 'A' group
  05-Jul-24   15:00
  Shilpa Medicare sizzles after Unicycive gets positive results in clinical trials of OLC
  05-Jul-24   14:52
  Manugraph India Ltd leads losers in 'B' group
  05-Jul-24   14:45
  NSE SME Nephro Care India rallies on listing day
  05-Jul-24   14:45
  ESAF SFB total deposits jumps 33% YoY in Q1
  05-Jul-24   14:43
Back Top